The week’s gainers and decliners after data readouts x

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases

San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics

Crowding in the autoimmune CAR T field brings recruitment challenges

Caribou selected a de-risked target and modality to take on multiplexed editing

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing

Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned

How the once-dominant cancer company has overhauled its strategy for long-term growth

Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset

Plus: Readouts from Sanofi-Teva, Bicycle and more